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An infant, the product of a full-term, uncomplicated pregnancy, had
mild respiratory distress at birth characterized by tachypnea and a small
right pneumothorax. His respiratory symptoms quickly resolved without
treatment. He was, however, oliguric and had a markedly distended
urinary bladder; the serum creatinine concentration was 3.5 mg/dl. An
abdominal ultrasound examination demonstrated bilateral hydronephro-
sis; the left kidney was 2.4 cm, the right 3.0 cm. A voiding cystourethro-
gram (VCUG) demonstrated grade TV/V vesicoureteral refiux on the left,
and posterior urethral valves were noted upon voiding. A urethral catheter
was left in place and fulguration of the valves was performed on the 7th
day of life.
Despite the absence of bladder outlet obstruction, the serum creatinine
remained elevated in the range of 3—4 mg/dl. The infant was treated with
a special diet, Similac PM 60/40 formula with added polycose and corn oil,
which produced a final caloric concentration of 40 calories/oz. Feedings
were provided via nasogastric tube by overnight continuous infusion.
Medications included supplemental sodium chloride, 4 mEq 3 times daily;
erythropoietin alpha, 400 units 3 times/week; an iron supplement; and
dihydrotachysterol (DHT), 0.1 mg every other day.
By 8 months of age, the patient was 68 cm in length and weighed 7,2 kg,
and the serum creatinine was 6.8 mg/dl. Another ultrasound examination
and VCUG demonstrated no urinary obstruction. He underwent bilateral
nephrectomy and placement of a subclavian catheter for hemodialysis.
Histocompatibility testing had shown that his father was blood-type
compatible and an HLA-1-haplotype match.
At 9 months of age, the infant received a living-related donor (paternal)
renal transplant. Immunosuppression consisted of methylprednisolone, 7
mg intravenously twice daily; azathioprine, 14 mg intravenously twice
daily; and antithymocyte globulin (ATG), 140mg intravenously daily. The
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absolute lymphocyte count (ALC) fell from 3000/mm3 preoperatively to
less than 1000/mm3 by the second postoperative day but subsequently rose
again. The dose of ATG was increased from 20 mg/kg to 40 mg/kg. The
ALC continued to rise, reaching 8000/mm3 by the 6th postoperative day.
At that point, the urine output was 4000 cc/day. The infant's temperature
rose to 40°C on the 6th postoperative day, however, and the urine output
fell to 400 mI/day over the next 3 days. The serum creatinine remained
stable at 0.2 mg/dl, but the BUN slowly rose from 4 mgfdl to 14 mg/dl.
Treatment with "pulse" methylprednisolone was begun on the 6th post-
operative day, and the fever quickly abated. Urine output slowly increased
over the next week. Administration of oral cyclosporine was begun on the
4th postoperative day, and therapeutic levels were achieved 4 days later.
On the 9th postoperative day, the urine output fell slightly. A radionuclide
scan (MAG 3) demonstrated mild ureteropelvic junction obstruction, but
it resolved spontaneously.
The patient's father had been found to be cytomegalovirus (CMV)-
antibody positive during the pretransplant evaluation. The infant's initial
assessment had suggested that he too was CMV-antibody positive, but
further analysis suggested that the antibody probably had been maternally
transmitted. Thus, the patient received treatment with intravenous gan-
cyclovir during the methylprednisolone pulse, and a course of intravenous
anti-CMV gamma globulin also was begun.
Currently, 8 months following renal transplantation, the patient is
receiving cyclosporine, 40 mg 3 times daily; azathioprine, 15 mg/day; and
prednisone, 5 mg/day. His serum creatinine is 0.3 mgldl, and he has grown
3.5 cm since receiving the transplant.
Discussion
DR. WILLIAM E. HARMON (Director, Pediatric Nephrology, Chil-
dren s Hospital; and Associate Professor of Pediatrics, Harvard
Medical School Boston, Massachusetts): The patient presented
today clearly demonstrates many of the problems associated with
the care of infants with chronic renal failure. The clinicians who
care for these infants must choose among various treatment
options, each of which has multiple complications and a high
mortality rate. In this case, the child's renal disease was discovered
almost immediately following birth; reconstructive urologic sur-
gery successfully relieved his urinary tract obstruction. Unfortu-
nately, severe renal damage had occurred in utero due to the
obstruction. Because of his severe chronic renal failure, the infant
developed myriad medical problems. Initially, aggressive nutri-
tional support and other conservative measures permitted him to
grow at an almost normal rate. Nevertheless his renal failure
progressed to the point at which conservative treatment was no
longer appropriate, and living-related-donor renal transplantation
was carried out before dialysis was required ("pre-emptive trans-
plantation"). The immediate post-transplant course was compli-
cated by events related to his young age and small size. Nonethe-
less he tolerated the procedure well, and his subsequent course
has been relatively uneventful. He has begun to grow and develop
normally because of his normal, stable renal function, and his
immunosuppressive medications have been lowered to very low,
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Table 1. Causes of ESRD in children and adults
Disease category
Children
(<18 years)a
Adults
(20—64 years)b
Urologic malformations 26% 4%
Renal dysplasia 17% 0.3%
Other congenital causes 15% 5%
Focal segmental 11% 2%
glomerulosclerosis
Other glomerulonephritides/ 14% 17%
immunologic
Hypertensive nephropathy 0% 22%
Diabetic nephropathy 0.1% 40%
All other causes 17% 10%
a Source: NAPRTCS.
b Source: USRDS.
Age at first treatment
"maintenance" levels. Although further complications and possi-
ble chronic graft dysfunction might arise in the future, this infant
likely will enter early childhood with normal physiologic status.
After reviewing the epidemiology, incidence, and etiology
of chronic renal failure in infancy, my discussion will include: (1)
the treatment choices, including the option of no treatment;
(2) the outcome of living-related-donor transplantation in infants;
(3) the outcome of cadaver-donor renal transplantation in chil-
dren; (4) the factors affecting growth prior to transplantation; and
(5) long-term management following transplantation in infants,
including chronic immunosuppression and problems with post-
transplant growth.
Chronic renal failure in children, particularly in infants, is
uncommon. Incidence figures generally come from national reg-
istry studies, such as the United States Renal Data System
(USRDS) or the North American Pediatric Renal Transplant
Cooperative Study (NAPRTCS). In both of these registries, data
are entered either when patients begin treatment with dialysis or
receive a renal transplant. The registries do not include informa-
tion about patients who receive only conservative management
and those who receive no treatment at all. Thus, the incidence
figures derived from those sources considerably underestimate the
true values. For instance, the USRDS recorded only 7 infants less
than 1 year of age who received treatment for end-stage renal
disease (ESRD) in 1977, compared to 59 in 1987 [1]. It is unlikely
that the incidence of chronic renal failure changed so dramatically
during that decade. More likely, renal transplantation became
more widely accepted as treatment for these infants. The most
recent data available from both sources suggest that approxi-
mately 2500 children less than 20 years of age begin treatment for
chronic renal failure in the United States annually; of these, about
100 are less than 2 years of age [2—41.
Table 1, which contains information from both USRDS and
NAPRTCS, illustrates that the diseases that cause ESRD in
children differ strikingly from those in adults. Inherited disorders
or congenital abnormalities of the urinary tract, particularly
obstructive uropathy, are the leading causes of chronic renal
failure in young children. Refiux nephropathy, the result of
another urologic malformation, is also a major cause of chronic
renal failure. Older children have a higher incidence of glomeru-
lar disorders, particularly focal segmental glomeruloscierosis. In
contrast, virtually no children develop end-stage renal disease due
to diabetic nephropathy or hypertension, the leading causes of
ESRD in adults. With this background, let me turn to what
Fig. 1. Two-year survival rates for children who were treated with dialysis(, living-donor (fl .;:), or cadaver-donor ( ) renal transplantation. The
children received their first ESRD treatment in 1989. (Data adapted from
USRDS with permission [2].)
pediatric nephrologists and transplant surgeons can do in the
1990s for infants such as the one presented here.
Treatment choices. The infant with chronic renal failure has the
same treatment options as do older patients: chronic dialysis,
renal transplantation, or no treatment. For adults, the choice
among these various options is generally left to the patient, with
careful guidance provided by the clinician. In the case of infants
and children, of course, the family must make the ultimate
choices. Unless the patient has severe neurologic damage or an
untreatable condition such as metastatic Wilms' tumor, the option
of withholding treatment is rarely considered for older children.
In the case of infants, however, the possibility of not initiating
treatment is often considered, and rightfully so. Infants unques-
tionably have higher mortality rates for both dialysis and renal
transplantation [2, 3]. Furthermore, early reports suggested that
these babies suffer severe and irreversible neurologic damage
during the first year of life, even if treatment were otherwise
successful [5]. Moreover, the impact of these burdensome treat-
ments on the family has been considered as part of the rationale
for withholding treatment that ordinarily would be provided to
older children.
On the other hand, by providing excellent nutritional support
and other conservative measures, as well as by adapting dialysis
and transplant techniques for the special needs of infants and
young children, outcomes have improved markedly in recent years
[6—9]. Indeed, nearly normal growth and development, including
neurologic development, are now common in infants treated by
either conservative measures or with chronic peritoneal dialysis.
Despite evidence that mortality for dialysis and renal transplan-
tation is greatest in the youngest patients (Fig. 1), the survival
rates are now considered acceptable by physicians and families
alike. Even though the decision to treat or not to treat an infant
must still be made on an individual basis, recent reports suggest
that, in general, withholding treatment may be no more valid for
infants than for older children. In our own practice, we strongly
believe that renal transplantation is appropriate for virtually all
infants with ESRD. Let me turn to the reasons why.
The choice between chronic dialysis and renal transplantation is
one that any patient with ESRD must consider. Adults must
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evaluate the relative risks of the various procedures as well as the
effect of each on their own rehabilitation potential and life setting.
For example, young adults with few secondary complications from
underlying disease most often choose transplantation. Conversely,
elderly patients with multiple cardiovascular risk factors or other
complications whose dialysis treatments are proceeding well often
perceive no additional benefits from transplantation. For children,
however, renal transplantation has been recognized as the treat-
ment of choice for many years [10]. This preference for transplan-
tation is based on the fact that children frequently grow and
develop normally following renal transplantation. Growth and
development can proceed appropriately in children only if a
normal physiologic state prevails. Despite the many advances in
dialysis techniques, a normal physiologic state currently cannot be
achieved by either hemodialysis or peritoneal dialysis. Dialysis is
unable to allow normal growth and development, thus blocking
attainment of total rehabilitation.
Infants pose a more complicated decision than do older chil-
dren. Early reports of extremely poor outcome of transplantation
in infants, either because of high mortality rate [11] or other
factors [5], led to a reconsideration of the role of transplantation
in the treatment of infants with ESRD. Additionally, improved
outcome of infants treated by dialysis, particularly peritoneal
dialysis [8], suggested that renal transpiantion might best be
postponed until an older age. Very few studies have directly
compared the outcomes of dialysis and transplantation in chil-
dren. A 1981 study had suggested that the long-term mortality of
the two procedures was similar [12]. Information from more
recent registry studies, however, indicates that mortality rates with
chronic dialysis are no better than those with transplantation and,
in fact, might be worse. As Figure 1 illustrates, information from
the USRDS demonstrates that 2-year mortality rates for chronic
dialysis appear worse for each age group of children, especially
very young children, than for transplantation using either living-
related or cadaver donors. In a recent NAPRTCS report, the
one-year patient survival rate for both chronic dialysis and renal
transplantation for children less than 2 years of age was approx-
imately 85%. Patient survival was also 85% for children 2 to 5
years of age who were treated with dialysis, whereas the survival
rate was 95% with renal transplantation [13]. Thus, the concept
that chronic dialysis is a therapeutic safe haven for children with
end-stage renal disease until they are either old enough or big
enough to safely undergo renal transplantation is not supported
by current data. Figure 2 demonstrates the actual change in
modes of treatment for the children less than 5 years of age who
received treatment for ESRD between 1985 and 1989. Three-year
mortality rates were disappointingly high, approximately 18%.
Most patients were initially treated with chronic dialysis; only
about 5% received pre-emptive renal transplants. By 2 years, only
25% were still being treated with chronic dialysis; 59% had a
functioning renal allograft. Thus, most clinicians appear to view
renal transplantation as an appropriate and probably preferred
mode of treatment for infants with ESRD, although a strong
consensus has not yet been reached.
Whether to use a living donor or a cadaveric donor for renal
transplantation is determined by whether a potential living donor
is available. For adults, living donors provide only 20% of all renal
allografts [2]. For children, living donors account for about 50%
[3]. In all age groups, the outcome for living-donor transplanta-
tion is superior to that for cadaver-donor transplantation. Data
from the 1993 USRDS report show a 2-year patient survival of
Months since onset of ESRD
Fig. 2. Changes of modes of therapy for children <5 years of age who
received their first ESRD treatment between 1985 and 1987. (Data adapted
from USRDS with permission [1]. , death;, transplant; ti, hemodialy-
sis; , peritoneal dialysis).
96% following living-related-donor transplantation, compared
with 90% for cadaver-donor transplantation, and a 2-year graft
survival of 87% for living-donor versus 73% for cadaver-donor
transplantation [2]. Data from the UCLA Registry suggested that
the half-life of a 1-haplotype-matched living-donor transplant is
12 years compared to only 7 years for a cadaver-donor transplant
[14]. Patient and graft survival rates for children are quite similar
to those for adults. The NAPRTCS reported a 96% 2-year patient
survival for children who received living-donor transplants com-
pared with 94% for cadaver transplants. Graft survival rates at 2
years were 88% for living donors versus 71% for cadaver donors
[3]. Although somewhat lower, the same trend was seen in infants.
For recipients less than 2 years of age, 2-year graft survival rates
of living-donor transplants were 75% compared with only 52% for
cadaver-donor transplants. Data from our own center are similar:
5-year patient and graft survival rates for infants less than 2 years
of age who received living-donor renal transplants were 86%; this
percentage contrasted with 38% graft survival and 70% patient
survival for those who received cadaver-donor transplants [6]. For
all age groups, including infants, therefore, superior outcomes are
achieved with living-donor renal transplantation.
Living-donor transplantation. Although living-donor transplan-
tation provides superior outcomes for recipients of all ages,
infants less than 2 years of age do not fare as well as older
individuals. A recent NAPRTCS analysis of the association be-
tween recipient age and risk of graft loss in children less than 18
years of age demonstrated a statistically significant, inverse rela-
tionship between recipient age and risk of graft loss [15]. These
data yielded proportional hazards analysis of graft failure for
recipients less than 6 years of age that identified factors related to
poor outcome in infants. The analysis demonstrated that the lack
of prophylactic antibody induction therapy (P =0.04),very young
recipient age (P = 0.05) and more than 5 pretranspiant blood
transfusions (P = 0.06) correlated with poor graft outcome.
The relationship between blood transfusion and graft outcome
deserves further examination. Previous data (from the late 1970s)
had suggested that blood transfusions improved graft survival for
adult recipients of cadaver-donor transplants [16]. Additionally, a
beneficial effect of donor-specific blood transfusions on the results
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Table 2. Causes of living-related-donor graft failure in children (%)
Recipient age, years
0—1 2—5 6—12 >13
Cause (n = 27) (n = 47) (n = 67) (n = 86)
Thrombosis 19 19 4 10
Acute rejection 11 13 21 15
Hyperacute rejection 7 6 6 5
Chronic rejection 11 28 31 30
Recurrence of disease 4 13 10 12
All other causes 15 19 22 20
Death 33 9 6 8
a Adapted from Ref. 15.
of living-donor transplantation also had been demonstrated
clearly [17]. More recent data, however, have failed to document
a beneficial effect of pretranspiant blood transfusion, perhaps
because of a general improvement in outcome for all transplant
recipients. Indeed, for the first time, reports from the UCLA
Transplant Registiy have even suggested that pretransplant blood
transfusions are associated with poor cadaver graft survival [18].
Analysis of data from NAPRTCS yields similar results [19]. In an
analysis of 1932 children receiving living-donor transplants be-
tween 1987 and 1991, 694 received transplants without prior
donor-specific transfusion, 42 received donor-specific transfusions
without immunosuppression, and 167 received donor-specific
transfusions with immunosuppression, generally azathioprine. At
2 years, patient and graft survival for all three groups of patients
were indistinguishable. Donor-specific transfusions had no dis-
cernible effect on graft survival. In an additional analysis of the
relationship between pretransplant random blood transfusion and
living-donor-graft outcome, an inverse relationship between blood
transfusions and graft outcome was found. For children who
received more than 5 pretranspiant blood transfusions, the risk of
graft loss was significantly greater than for those who had received
fewer than 5 transfusions (P = 0.001). Overall, pretranspiant
blood transfusions have no discernible beneficial effect on the
outcome of living-donor transplants in children and may be
associated with worse outcome.
The causes of graft failure following living-donor renal trans-
plantation in children of various age groups are shown in Table 2.
For statistical purposes, death is considered a cause of "graft
failure" even if the graft is functioning at the time of death. The
table represents two main causes of graft failure in younger
children: graft thrombosis and death from an unrelated cause
(such as infection). Although graft thrombosis rarely causes graft
failure in older children and adults, it accounts for a substantial
percentage of graft failure in young children. In a 1991 NAPRTCS
report, graft thrombosis accounted for 23% of all graft failures
within the first 2 months following transplantation in children less
than 6 years of age [20]. By contrast, thrombosis caused only 5%
of graft losses in children 6 to 10 years of age, and graft
thrombosis did not occur in any children older than 12 years.
There seemed to be no "center effect" or other technical causes
associated with the incidence of thrombosis. Infants and young
children who received pre-emptive renal transplants, that is,
without a prior course of dialysis, seemed to be slightly more
prone to graft thrombosis; perhaps residual native renal function
predisposes to graft thrombosis. Unfortunately, knowing that
thrombosis is a risk in this young age group has not yet led to a
decrease in its frequency [3].
Death with a functioning graft following living-donor renal
transplantation is more frequent in infants than in older age
groups. In an analysis from our own center, 5-year graft survival
following renal transplantation was 86% in infants less than 2
years of age compared with 98% in children over 2 years of age
[6]. Similar results have been reported from other centers [7]. This
difference in the mortality rate in the patients under age 2 is
unacceptably high. In an analysis of more than 3000 renal
transplants reported to NAPRTCS between 1987 and 1993, 397
were living-donor transplants in children less than 6 years of age.
A statistically significant relationship was found between the risk
of graft loss and recipient age, with the highest risk in the infants
less than 2 years of age. If deaths as a cause of graft failure are
removed from the analysis, the effect of recipient age on living-
donor graft survival is eliminated [15j. This analysis suggests that
"excess graft loss" in young recipients of living-donor renal
transplants might be due entirely to the higher mortality in this
age group, the mortality resulting not from true graft failure but
from non-renal causes. A separate NAPRTCS report listed 136
deaths in 2500 children; the average death rate was 25 deaths per
one thousand patient-years [21]. Deaths were primarily due to
infections, but cardiovascular causes, hemorrhage, and malignan-
cies each represented a substantial proportion. A Cox propor-
tional hazards analysis identified two factors as significant risk
factors for mortality: very young recipient age (less than 2 years of
age) and graft non-function at 30 days. Thus for those infants who
did lose graft function— either because of technical reasons, acute
tubular necrosis, or rejection—the risk of death was strikingly
high. Therefore, attention to the technical details of the transplant
and prompt treatment of rejection episodes might lead to im-
provement in morbidity and mortality rates in the very young child
undergoing living-donor transplantation.
Overall, living-donor transplantation now provides the best
opportunity for good outcome for infants with chronic renal
failure. Current strategies for improving graft outcome in young
infants include provision of good pretranspiant nutrition to pro-
mote growth and to avoid malnutrition, avoidance of blood
transfusions, and provision of prophylactic antibody treatment to
delay or prevent early acute rejection episodes. Unfortunately,
mortality rates in this very young age group remain quite high.
Clearly, more study is needed to elucidate the causes of death and
to identify preventive strategies.
Cadaver-donor transplantation. Cadaver-donor transplantation
generally is less successful than is living-donor transplantation in
all age groups. This fact is particularly evident in infants, for whom
the discrepancy between the outcome of cadaver-donor and
living-related-donor transplantation is greatest [3, 6]. Recent
reports from several centers, however, have described improved
outcome following cadaver-donor transplantation in infants re-
sulting from correction of the unique problems encountered in
this age group [22, 23].
Figure 3 shows the relationship between recipient age and the
risk of graft loss following cadaver-donor renal transplantation in
children. As with living-donor transplantation, a striking inverse
relationship exists between risk of graft loss and recipient age,
with the highest risk encountered in the very young, generally less
than 2 years of age. Causes of graft failure in young infants include
graft thrombosis and acute rejection; death with a functioning
graft also is common. Risk factors for poor outcome have been
defined by NAPRTCS [15]. The most important of these include:
previous transplant (relative risk [RR] = 3.4, P < 0.001); lack of
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prophylactic antibody induction therapy (RR = 1.75, P 0.003);
and young donor age (RR = 1.33, P = 0.02). Let me expand on
the issues of graft thrombosis, young donor age, and induction
therapy.
Graft thrombosis is a unique cause of graft loss following
cadaver-donor transplantation in children. Unlike living-donor
transplantation, however, the risk of graft thrombosis following
cadaver-donor renal transplantation is not strongly related to
young recipient age. Rather, young donor age is more closely
related to the likelihood of graft thrombosis [201. In keeping with
the inverse relationship between graft thrombosis and donor age,
the highest risk is found when infant cadaver kidneys are used,
whereas rarely does thrombosis follow transplantation of adult
cadaver kidneys into children. As I will note in a moment,
reducing the use of young cadaver kidneys for young recipients
has reduced the incidence of graft thrombosis and has improved
overall graft survival [24].
Graft thrombosis is not the only cause of graft losses from
young donors. The relationship between donor age and the risk of
graft failure is shown in Figure 4 [25]. As I mentioned, the use of
grafts from very young donors is related to the highest risk of graft
loss. This risk decreases as donor age increases toward that of the
"ideal" donor, who is about 21 years of age. The risk then
increases with increasing donor age. The risk of graft loss is
equivalent for kidneys obtained from donors 6 years of age and
from donors 55 years of age. The poor outcome associated with
young donor age is a particularly important issue for pediatric
recipients of cadaver-donor renal transplants because of a previ-
ous method of allocation of grafts. The United Network for Organ
Sharing (UNOS), the organ procurement and transplant network
in the United States, has always given preference to children
awaiting renal transplantation. The method of implementing that
preference prior to 1990 was to offer grafts obtained from donors
less than 10 years of age first to recipients less than 15 years of age
[24]. This method of allocation did result in a shorter waiting time
for children than for adults, but, unfortunately, the resulting graft
survival was significantly worse than it was for adults.
In 1990, the method of allocation of grafts to children was
changed in the United States. Children were given additional
priority "points" rather than having absolute preference for grafts
from particular sources. This change produced three important
results: First, grafts obtained from young donors were allocated
both to adults and children, and the proportion of young cadaver
grafts transplanted into children decreased substantially. Second,
children less than 10 years of age continued to have shorter
waiting times for cadaveric renal transplantation than did adults.
Third, graft survival in pediatric recipients improved significantly
during this time. While overall graft survival generally has im-
proved, the percentage increase in graft survival for children less
than 15 years of age has been significantly greater than that for
adults [24]. Indeed, graft survival for children older than 5 years of
age is now the same as it is for adults [24]; this finding suggests
that one of the principal causes for the previously poor survival
rates was related to the allocation system. In effect, under the old
system, children under the age of 15 years were receiving less than
optimal grafts because of the allocation system. Now that they
receive grafts from the same type of donors as adults, their graft
survival is about the same. Unfortunately, graft survival of the
youngest recipients still remains inferior to that of older children
and adults; other factors probably are responsible for poor
outcome.
One of those factors might be early posttransplantation immu-
nosuppression. As I indicated, one of the risk factors associated
with graft failure in infants who receive either living-donor or
cadaver-donor kidneys is the lack of antibody-based induction
therapy, that is, the use of prophylactic antilymphocyte serum or
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Fig. 3. Relationship between recipient age and the risk of graft loss for
children <18 years of age who received cadaver-donor renal transplants
between 1987 and 1994,
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of graft loss from all causes for pediatric recipients of cadaver-donor renal
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and 55-year-old donors. (Reproduced with permission from Ref. 25.)
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OKT3 [15]. Reviews of renal transplantation in adults have failed
to show a substantial effect of induction therapy on eventual graft
function [26]. By contrast, data from NAPRTCS have shown that
for all children who receive living-donor transplants, induction
therapy is associated with a significantly longer time to the first
rejection episode [31. Moreover, for pediatric recipients of cadav-
er-donor transplants, 3-year graft survival is significantly better in
those who have received antibody-induction therapy (70%) than
in those who have not (59%). As I already have noted, the
beneficial effect of antibody-induction therapy for infants seems to
be even greater [15]. Moreover, those centers that have reported
excellent outcome of either living-donor or cadaver-donor trans-
plants in infants all have included antibody induction as part of
their immunosuppression strategy [6, 7, 221.
Pretranspiant growth of the uremic infant. Several procedures
clearly have been associated with superior outcome for renal
transplantation in infants and children. Important among these
are the sources of the grafts themselves. The best outcome is
obtained when a living-related donor is used for the transplant. In
virtually all these instances, the infant receives the graft from a
parent. Even in cadaver-donor transplantation, the preferential
source of the graft is an adult. In either case, the infant must be
big enough to be able to receive a kidney from an adult donor. But
uremia results in substantial growth failure [27]. The newborn
infant with renal failure must double or triple in size to be big
enough to receive an adult graft. Growth failure in an infant,
therefore, could be an obvious impediment to successful renal
transplantation. Although many programs have identified 10 kg as
the minimum recipient size for renal transplantation, successful
transplantation with adult grafts has been achieved in substan-
tially smaller infants, even those as small as 5—6 kg [6, 7]. The
technical difficulties associated with successful transplantation
under these circumstances pertain more to the vascular anasto-
moses than to the actual size of the graft. For successful trans-
plantation, the anastomosis of the adult renal artery to the infant's
aorta should not result in substantial compromise of flow in either
of those vessels. Additionally, perfusion of the large adult graft by
the infant's cardiovascular system is very important. Dramatic
differences between the blood flow requirements of the adult graft
and the cardiac output of the infant might be partly responsible
for the high incidence of graft thrombosis under these circum-
stances [201.
What accounts for the growth failure in uremic infants? We
know that several factors are important, including thyroid func-
tion, metabolic status, acid-base equilibrium, and the degree of
osteodystrophy [28]. Perhaps the most important factor, however,
is the infant's caloric intake. Growth in the first year of life is
highly energy dependent. Recent studies have confirmed that
gastrointestinal motility is particularly abnormal in uremic infants,
possibly because of abnormally high concentrations of circulating
peptides that control gut motility [29]. Uremic infants frequently
suffer from gastroesophageal reflux and frequent vomiting. The
resulting feeding disorders are well recognized in these infants. As
a general rule, uremic infants do not seem hungry, eat poorly, tire
easily during feeding, and frequently have severe vomiting. All
these abnormalities can lead to caloric deficiency and consequent
growth retardation.
Feedings via nasogastric tube, either continuously overnight or
around the clock, have proven beneficial [9, 30]. Many of these
infants require fluid restriction, and formula concentrations as
high as 60 calories/ounce are sometimes necessary [31]. We
reviewed our own experience with nutritional therapy for uremic
infants [9]. Uremic infants were fed formulas that were enriched
with polycose and corn oil; our goal was to provide 8—12 calo-
ries/cm of length and 0.15 g protein/cm of length. Of 24 infants
who received this nutritional therapy, only 2 had not reached a
size large enough to receive an adult renal allograft by 18 months.
Overall, therefore, by providing appropriate treatment for under-
lying metabolic abnormalities, such as bicarbonate for metabolic
acidosis, 1,25-dihydroxy-vitamin D for osteodystrophy, erythro-
poietin for anemia, and most important, appropriate diet, virtually
all uremic infants should be able to grow to the size necessary to
receive an adult renal transplant.
Long-term management. Following successful renal transplanta-
tion, the child must receive chronic immunosuppression to pre-
vent rejection of the graft. The growth and development of the
child can influence the choices of both the types and amounts of
this immunosuppression; conversely, the immunosuppression can
affect the child's growth and development.
Corticosteroids have been a mainstay of chronic immunosup-
pression for organ transplantation for many decades. Unfortu-
nately, chronic treatment with corticosteroids has many long-
term, adverse effects. Among these effects are hypertension,
orthopedic abnormalities (particularly aseptic necrosis), cataracts,
accelerated atherosclerosis, and growth retardation in children.
Many of these problems can be partially prevented by provision of
corticosteroids on an alternate-day schedule. Several studies have
demonstrated a clear growth advantage for children who receive
corticosteroids on an alternate-day rather than a daily schedule
[32—34]. Although the effectiveness of the immunosuppression
provided by this schedule was unknown when first tried, two
recent rigorous studies have demonstrated that children who
receive alternate-day corticosteroids are no more likely to have
rejection episodes than are those who receive an equivalent
amount on a daily basis [33, 34]. Despite this information,
however, less than 30% of children currently receive corticoste-
roids post transplantation on an alternate-day schedule [35]. 1
believe that this deficiency in our collective practice must be
corrected as soon as possible. Another strategy for avoiding
complications from corticosteroids is weaning children off this
therapy entirely. Although such weaning is successful in as many
as 60% of children initially, only about 30% can be maintained
long term without corticosteroids [36].
Virtually all children with renal allografts are currently treated
with cyclosporine to achieve chronic immunosuppression [3]. The
pharmacokinetics of cyclosporine in children are generally differ-
ent from those in adults. Children frequently absorb cyclosporine
from their gastrointestinal tract more erratically, and metabolize
it more quickly, than do adults. Thus, children frequently require
higher (on a per kg basis) and more frequent doses of the drug.
Cyclosporine also has several long-term adverse effects, including
hypertension, decreased renal function, hirsutism, and gingival
hyperplasia. Because of these problems, particularly impaired
renal function, many programs have chosen to taper cyclosporine
doses in renal transplant recipients. A 1993 review of data from
NAPRTCS demonstrated that infants generally received very high
doses of cyclosporine immediately following transplantation but
that those doses were reduced during the next 3 years to a level
approximately one-third of the original [37]. This tapering of the
dose was accomplished both because the patients grew (and thus
their proportional dose diminished), but also because the doses
were deliberately tapered (Fig. 5). Recent studies have suggested,
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however, that tapering of cyclosporine can have long-term adverse
effects [37, 38]. Children receiving lower cyclosporine doses were
more likely to have late acute rejection episodes and graft failure
than were those treated with higher doses.
Appropriate growth following transplantation is a major prob-
lem for children with chronic renal failure, Indeed, the potential
for growth following transplantation has been the principal indi-
cation for early or pre-emptive transplantation and for giving
preference to children awaiting cadaver transplantation [10]. As I
noted earlier, growth retardation is an almost universal conse-
quence of uremia in children. Successful renal transplantation can
reverse growth failure and provide the child with the potential for
normal or even accelerated growth [35].
The most rapid growth following transplantation generally
occurs in infants [3, 35]. Many of these infants can undergo
"catch-up" growth, growing more rapidly than expected and
making up for growth that was lost during conservative treatment
or dialysis. Despite this early growth, their final adult height
frequently remains suboptimal. Recent reviews of growth follow-
ing transplantation in children indicate that the growth pattern
frequently is unpredictable [39]. Many children demonstrate
accelerated growth for several years following transplantation,
and they subsequently grow at a normal rate for several more
years. Unfortunately, many manifest growth retardation again
later despite continuing, albeit often reduced, graft function (Fig.
6). This later growth retardation frequently coincides with the
onset of renal dysfunction associated with chronic rejection.
Endocrinologic evaluation has demonstrated that many of these
children have a relative growth hormone secretory defect [40].
Administration of growth hormone can restore normal growth
patterns, but some children experience acceleration of the renal
dysfunction [41, 42].
Conclusion. I and virtually all pediatric nephrologists consider
renal transplantation the treatment of choice for children with
uremia. Virtually all infants and children with chronic renal
failure are candidates for renal transplantation, and transplants
are often successful. Currently, the best possible donor for an
infant or young child is a living-related donor, most commonly a
parent. Several unique issues arise with renal transplantation in
Age, years
Fig. 6. Representative growth curve for a child receiving a renal transplant.
The child was growth retarded at the time of the transplant [1], after which
he had accelerated growth for almost 6 years. At that point [2], the growth
rate was normal for 3 years, but growth failure occurred concomitantly
with the onset of chronic allograft rejection [3]. A normal rate was
re-established by treatment with recombinant human growth hormone [4].
(Reproduced with permission from Ref. 35.)
infants and young children. Included among these are graft
thrombosis, the early diagnosis of rejection, and the optimal
allocation of cadaver grafts, particularly those from young donors.
Infants undergoing renal transplantation also experience special
problems with chronic immunosuppression, particularly with re-
spect to the doses of corticosteroids and cyclosporine. Recent
studies have addressed these issues and significant progress has
been achieved. All this work has yielded marked improvements in
graft and patient survival following renal transplantation in infants
over the last decade. Many programs have achieved equivalent
graft survival outcome in infants and in older children and adults.
Growth following transplantation in infants generally is excellent,
at least in the short term.
Despite this progress, however, many unanswered questions
remain. Early diagnosis and prevention of acute rejection epi-
sodes undoubtedly will improve both the morbidity and mortality
of the procedure. Why infants undergoing renal transplantation
have such high mortality rates is still a puzzle. Research into the
mechanisms of chronic rejection and its prevention obviously are
necessary. Finally, means must be found to maintain normal
growth rates following transplantation if this treatment is to be
truly successful for children.
Questions and answers
Dn. NIcoLAos E. MADIA5 (Chief Division of Nephrology, New
England Medical Center, Boston, Massachusetts): In presenting the
relationship of cyclosporine to graft outcomes, you plotted doses
of cyclosporine. Also, you mentioned in passing that the absorp-
tion and handling of cyclosporine is changing across age groups.
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Fig. 5. Changes in the absolute dose of cyclosporine (X) and the recipients'
mean weight (closed circles) between I and 36 months after renal trans-
plantation in children C 5 years old. (Reproduced with permission from
Ref. 37.)
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To what extent might your conclusions have been affected if you
had used cyclosporine blood levels rather than cyclosporine doses
in your analysis?
DR. HARMON: Our conclusions indeed might have been differ-
ent, and that is one of the problems associated with the use of
registry data. The data contain no consistent measurement of
cyclosporine blood levels. With 90 different centers providing
information, and with at least 4 different methods of measuring
cyclosporine levels, we could not discover any correlation because
the data are far too scattered. I'm sure that there is a relationship,
but registry data can't demonstrate it.
DR. JOHN T. HARRINOTON (Dean for Academic Affairs, Tufts
University School of Medicine, Boston, Massachusetts): You men-
tioned that one-third of the grafts lost were due to death, but I
didn't hear you say what the specific causes of death were. Second,
is there a learning curve, so that the death rate might have fallen
in your or other institutions over a 5-year period?
DR. HARMON: That's an interesting question, and I haven't
thought about it in those terms. Several studies have shown that
it's not good to be the first patient to get any treatment such as
cardiac transplantation [43]. We analyzed mortality following
transplantation in our institution, reporting 15-year patient sur-
vival [44]. One of the most important factors associated with
mortality was our own inexperience. That is, the mortality rate in
all age groups was highest during the first 5 years of our
experience. UNOS has asked the same question you have by
analyzing the relationship between the number of transplants
performed at a center and its patient and graft survival. Early data
from UNOS suggest that the number of heart transplants per-
formed at a center is directly related to outcome: the largest
centers have the best graft survival [45]. A similar relationship
might exist for liver transplantation, but center size might not be
as important for renal transplantation. Renal transplantation is
quite mature now so most centers have enough experience, even
the ones with small numbers of transplant patients.
Overall, I think the learning curve is important. The causes of
death for children are the same as for adult transplant recipients:
the major early cause of death is infection. The second most
frequent cause of death is related to cardiovascular problems,
which probably means shock or cardiac arrest. I haven't discussed
infections in children following transplantation. Of the last 2
patients who died in our institution, one died of varicella and the
other died of respiratory syncytial virus. Thus infections are a
major problem for transplant recipients, and children have un-
usual infections.
DR. RICHARD LAFAYETFE (Division of Nephrology, New England
Medical Center): The data presented demonstrating a survival
advantage for transplantation over dialysis appear compelling.
However, the survival curves appear similar to those in the adult
ESRD population when selection bias is uncorrected. To what
extent does selection bias influence survival data in the pediatric
ESRD population? Second, as survival is poor in children on
dialysis, are efforts being made to determine whether increased
dose of dialysis, nutritional support, or other interventions might
improve the outcome?
DR. HARMON: That is a very important observation and goes
right to the Achilles' heel of registry data. All the data are
retrospective and simply can't answer those types of questions.
The best way to answer the question is to do a controlled
randomized trial. However, if we tried to randomize infants into
either dialysis or transplantation cohorts, we would never be able
to register anyone in the study. Centers have biases, and the
number of patients is small, so the question is very difficult to
answer. The bias in the pediatric nephrologic community has been
toward transplantation. We try to perform transplants in as many
children as possible. There aren't a lot of young patients who are
receiving chronic dialysis treatment. The data that demonstrate a
higher mortality for dialysis than for transplantation in the 2- to
5-year age group are brand new. A number of centers are very
surprised by that report and feel that there is something wrong
with that analysis. Perhaps there is a selection bias. Perhaps the
sickest patients have only been offered dialysis and have not been
considered candidates for transplantation.
Pediatric dialysis is far behind adult dialysis in terms of deter-
mining an "adequate dose." As Figure 2 shows, the majority of
young patients are treated with peritoneal dialysis. Quantitating
peritoneal dialysis is a difficult issue. I would suggest, however,
that because of their small size and because most small children
are treated with peritoneal dialysis on cyclers, they probably
receive a higher "dose" of peritoneal dialysis than do adults.
Nutrition is another issue that has had a strong emphasis in
pediatric programs for a long time. The majority of young dialysis
patients receive nasogastric or gastrostomy feedings. As for the
causes of excess mortality in dialysis, we haven't come up with
satisfying answers. For the youngest age group, a surprising cause
is sudden death. Some children under one year of age have
unexplained cardiac arrest. We have had several incidents of that
in our own institution, and we haven't been able to determine a
cause for it. Registry data will be helpful in putting together the
collective experience of a large number of small programs. At this
point, I won't be able to provide any better answers for your
specific questions.
DR. MADIAS: You referred to growth in terms of increasing
height and weight. Does growth correlate with other indices such
as bone age, head circumference, and cognitive development?
Also, could you please summarize the indications for growth
hormone administration and the potential concerns associated
with this treatment?
DR. HARMON: The term "growth" should never be used by
itself. As pediatricians, we try to say "growth and development."
Development is just as important as growth. If a child has grown
well but is neurologically, socially, and sexually delayed, that's not
really a "success." However, growth is the easiest thing to
measure. A number of studies have assessed neuropsychologic
development as well as growth and have compared the develop-
ment of children treated with dialysis with that of children treated
with transplantation. Indeed, poor school performance, neuro-
logic disorders, seizure frequency, and so on are virtually always
much more frequent in the children who are being dialyzed than
in those who received transplants. Sequential studies have been
performed in children during dialysis, and then following trans-
plant. Neuropsychologic activity is always worse on dialysis than it
is following transplantation. I think transplantation, in addition to
allowing children to grow better, allows them to develop better.
Your question about growth hormone is a very interesting one.
In the first year of life, growth hormone is not necessary; if we
provide sufficient calories, uremic infants will grow. After the first
year of life, for children treated with either conservative manage-
ment or dialysis, growth hormone is unquestionably beneficial. A
uremic child who has had growth retardation will grow at a normal
or accelerated rate as soon as growth hormone treatment is
begun. Following transplantation, children who have good graft
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function and are receiving a low dose of steroids, preferably on an
alternate-day dose schedule, will grow normally. In fact, most of
the very young children will grow at an accelerated rate, as I have
shown. However, years after transplantation—particularly after
the onset of chronic rejection—some of the children fall off the
growth curves again. We've treated a number of those children
with growth hormone, and virtually all of them then grew at
normal rates.
In the transplant setting, graft function can be adversely
affected by growth hormone. We've seen that repeatedly, but we
don't understand the mechanism of it. A preliminary report from
a multicenter European study earlier this year examined children
who received growth hormone following renal transplantation.
Those children who received growth hormone grew better than
those who did not, but they also had a higher rate of acute
rejection in the first year following transplantation [46}. There
might be an immunostimulatory effect of growth hormone. In
addition, other reasons might account for decreased graft func-
tion. One case report described a pediatric renal transplant
recipient who received growth hormone. The serum creatinine
rose from 1 mg/dl to approximately 3 mgldl in a few months.
Discontinuation of the growth hormone was associated with a fall
of the creatinine back to 1 mg/dl [47]. In the transplant situation,
some complications of growth hormone might be associated with
decreased renal function.
DR. ANDREW S. LEVEY (Division of Nephrology, New England
Medical Center): Could you tell us more about the ethical, social,
and financial issues of treating neonates who have renal failure?
DR. HARMON: The ethical issues are straightforward—you have
to balance the benefits and risks. Obviously there are severe risks
for the infant receiving these treatments. We do know that the
mortality rates in these children are higher than they are in adults.
However, the majority of children who receive living-related
donor and cadaver donor transplants survive the procedure. From
that perspective, renal transplantation is a reasonable approach.
Almost 80% of these transplants succeed, at least for the short
term, and the benefits to the child are apparent in that setting. But
sometimes pediatricians wonder whether the technical success
justifies having these children have a life full of medications and
complications, especially when they grow up and are not normal
healthy adults. If the goal of childhood is to become a normal
adult, then we've failed. If that were the sole measure, none of our
patients would be a "success." Yet we've treated many patients
who have grown up, reached a normal adult height, gone to
college, and had their own families. They have had somewhat of
a difficult time in doing these things, but I believe that they have
succeeded. A good measure is to ask a 40-year-old with cancer to
undertake a difficult series of treatments with a 50% 10-year
survival rate. How many of these patients would turn it down? If
we agree that 10 years of a child's life is equivalent to 10 years of
a 40-year-old's life, I think you will understand why we recom-
mend transplantation. Years of life are probably a good measure
of outcome, rather than successful achievement of a "normal"
adulthood. We'd love all our patients to achieve normal adult-
hood, but we don't think that is the sole measure of success.
What about the financial issues? Transplantation costs for an
infant are at least double those for an adult because the compli-
cation rates are higher, hospitalization is longer, and so on. But if
years of life are the measure of success, these added costs are a
reasonable investment. Children survive longer than adults do.
DR. HARRINOTON: I have several questions. First, is there any
difference for the child whether the kidney comes from the
mother or father? Second, what are the complications 10 years
after renal transplantation? Third, is cancer a problem in these
children as it is in adults?
Da. HARMON: We haven't discerned a difference yet between
maternal or paternal donor kidneys. We looked at that question
using the NAPRTCS registry, and couldn't ascertain a difference
in outcome. Hypotheses have surfaced concerning non-inherited
maternal antigens in cadaver transplantation, but there does not
seem to be any effect in living-donor transplantation. In the early
years of transplantation, mothers were donors more frequently
than were fathers. More recently, the mix of donors is more equal.
We leave it up to the parents to choose. Size doesn't seem to make
a lot of difference.
Long-term complications are troubling. The biggest complica-
tion is the onset of chronic graft dysfunction, which we've termed
"chronic rejection." Other long-term issues include cardiovascu-
lar problems. We have only recently begun to pay attention to
blood lipid and cholesterol levels, which are strikingly elevated in
some of these patients. They are somewhat better in the patients
treated with alternate-day prednisone than those given daily
prednisone. But when we assessed our 15-year patient survival,
the long-term patient mortality was related to cardiovascular
deaths, including myocardial infarction, in some patients who
were in their 20s and 30s.
Your third question related to malignancy. Yes, it certainly
occurs in children. The NAPRTCS registry has identified about 30
children of 3000 who have had serious malignancies, including
lymphomas. Malignancies are probably related to the amount of
immunosuppression, but no medication stands out as the specific
cause. Unfortunately, the typical patient with a malignancy has
received growth hormone, 2 transplants, 3 "pulses" with OKT3,
steroids, and so on. Finding an individual factor is impossible. In
our own program, we can report 20-year followups. We're starting
to see skin neoplasia, such as basal cell carcinomas, in some of our
young adults.
DR. MAmAs: You talked about adverse effects of the daily
administration of steroids on various parameters. Is there any
substantial experience on complete steroid withdrawal in pediatric
renal transplant recipients?
DR. HARMON: Some programs have tried aggressively to with-
draw steroids from their pediatric patients. They are initially
successful in about 60% of patients, but in one-half of those 60%
steroids have to be restarted because of late rejection episodes.
We're trying to identit' the recipients who might be the best
candidates. We need to look for signs of long-term tolerance to
their donors. These may be the group of patients who might have
the least risk when prednisone is withdrawn. Most programs feel
that the risks of discontinuing steroid administration outweigh the
benefits for the majority of patients at the present time.
DR. BRIAN PEREIRA (Division of Nephrology, New England
Medical Center): You showed a graph in which survival tended to
drop off in the 12- to 18-year age group in living-related but not
cadaveric donors (Fig. 3). Can you tell us more about why that
happens?
Da. HARMoN: I haven't done that study yet. We knew from our
experience that the young child had the highest risk of graft
failure. When we did the analysis, the result that you noted
appeared, and it was surprising to us. The most obvious proposal
would be to suggest that adolescents don't comply with their
medications, or that they stop taking them altogether, have
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rejection episodes, and end up back on dialysis. However, if that
were true for recipients of living-related donor transplants, I
would expect it to be true for the recipients of cadaver transplants
also. It isn't. Thus we don't know the cause, and the analysis has
not been done yet.
DR. PEREIRA: If young donors are not good enough for children,
should we be harvesting kidneys from these donors at all?
DR. HARMON: There are 25,000 people awaiting renal trans-
plant now. There are 8,000 cadaver donors each year. Many
transplant programs have been proposing what we call "the
expanded donor pooi." That is, we should use older and younger
donors. We think that it might be better to put the kidneys from
young donors into older recipients. Being a young recipient is a
very high risk factor for graft failure. Putting the highest-risk
kidney into the highest-risk recipient multiplies the risk factors.
Indeed, currently the vast majority of kidneys that are recovered
from young donors actually go into adult recipients.
DR. AJAY SINGH (Division of Nephrology, New England Medical
Center): To what extent does the immaturity of the immune
system in young or very young recipients influence graft failure?
What role does passive maternal immunity play in graft failure?
Finally, how do you handle childhood immunizations in children
who are immunosuppressed?
DR. HARMON: The young immune system has been studied to
some extent. Lymphocyte counts are significantly higher in young
recipients. All of the T-cell subsets are higher, although a
difference exists in the balance of these subsets related to age.
Some studies of immune responsiveness, such as blastogenesis,
typically suggest more responsiveness in young recipients than in
older children and adults. Thus, there have been suggestions that
children are more "immunoresponsive" than are adults. There-
fore, they might need more immunosuppression. On the other
hand, very young children, that is, babies less than one year of age,
have decreased antibody levels, and they don't respond to certain
vaccinations.
Your second question was about passive maternal immunity.
Neonatal tolerance is clearly evident in mice but does not apply in
humans. Neonatal tolerance might be possible at 20 weeks of
gestation. Infants who received in-utero blood transfusions devel-
oped graft-versus-host disease from the transfused lymphocytes
after they were born [48]. However, at full gestation, children are
fully immunocompetent in terms of graft rejection, as has been
demonstrated in infant heart transplant recipients [49J.
Immunizations are very important. Death due to infection is the
leading cause of mortality following transplantation. Immuniza-
tion following transplantation is difficult because the children are
chronically immunosuppressed and don't respond well. We try to
have the children immunized prior to transplantation rather than
afterward.
DR. MADIAS: I was struck by the incidence of graft thrombosis
as a cause of graft failure. Is the current understanding that this
complication is more or less a technical issue?
DR. HARMON: In the cadaver transplant group, graft failure
clearly is related to donor age. Thrombosis might be a technical
issue, or it might be due to the fact that the vasculature of the
young patient is more reactive than that of the older patient. The
transplant surgeons tell us that the young graft vessels seem to be
very reactive. In living-related donor transplantation, the age of
the recipient is the major risk factor. Every transplant surgeon
thinks it's a technical issue in this setting. But thrombosis doesn't
seem to be clustered. When we looked at the 70 institutions of
NAPRTCS, there was no obvious pattern. The size of the program
didn't seem to matter. Thrombosis seemed to be a random event.
DR. MADIAs: Does the early use of cyclosporine appear to affect
the incidence of graft thrombosis?
DR. HARMON: Prior to the use of cyclosporine, there was also a
problem of thrombosis. In many programs, the use of cyclosporine
is reserved until after induction therapy has stopped. Many of the
children who had graft failure had never received cyclosporine.
DR. MICHAEL LINSHAW (Chief Pediatric Nephrology, New En-
gland Medical Center): Could you comment about the integrity of
the families? What happens to the donor? What happens to the
siblings of a child going through a potential rejection or having to
go back on dialysis or receive another transplant?
DR. HARMON: Dr. Levey alluded to this important problem in
terms of the ethical issues. A family that has a chronically ill child
is at risk. The other children in the family tend to be ignored
because there simply is not enough time for them. The effects on
the donor are a major issue. When the child does well, it's fine for
the donor. When the child doesn't do well, or in the worst
situation, when the child dies, the donor has a certain amount of
guilt. Perhaps donors feel that they contributed to the death. Yet,
even in situations in which the recipient dies or loses the graft,
most often donors feel that the donation was worthwhile. They've
done whatever they could do to achieve a good outcome for the
recipient. Generally, we haven't seen problems in the donors even
when the outcome has been bad. We recently looked at the
integrity of the family and the cost to families of transplantation in
infants. We were surprised by the results. Our prejudice was that
transplantation exacted a devastating cost from the family. But the
number of intact families was exactly the same after the transplant
as it was before. The number of families who had other children
after the transplant was about the national average. Despite the
hardships, transplantation did not devastate the family structure.
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